Clasificación en acciones
#6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Capitalización bursátil
$1.96B
Comercio GH Research PLC (GHRS)
Precio GHRS con Capital del mercado a B
Capitalización de mercado de GH Research PLC(GHRS)
Capitalización bursátil: $1.96B
A fecha de August 2026, GH Research PLC tiene una capitalización de mercado de $1.96B. Esto convierte a GH Research PLC en la 6594th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de GH Research PLC desde 2021 hasta 2026
GHRS en comparación con los más populares 5 títulos stocks
| Precio por GHRS |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.532T
|
+282,710.35%
|
|
|
|
|
$4.608T
|
+235,498.50%
|
|
|
|
|
$4.096T
|
+209,294.51%
|
|
|
|
|
$3.748T
|
+191,543.07%
|
|
|
|
|
$2.761T
|
+141,077.90%
|
